Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2019 - 2021)

Lyell Immunopharma's Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $1.0 billion for Q1 2021.

• In Q1 2021, Preferred Stock Liabilities changed N/A year-over-year to $1.0 billion; the TTM figure through Mar 2021 stood at $1.0 billion (changed N/A YoY), while the FY2020 annual figure was $1.0 billion, up 94.73% from the prior year.
• Preferred Stock Liabilities came in at $1.0 billion for Q1 2021 at Lyell Immunopharma, roughly flat from $1.0 billion in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $1.0 billion in Q2 2020 to a low of $519.2 million in Q4 2019.
• A 3-year average of $912.6 million and a median of $1.0 billion in 2020 frame the typical range for Preferred Stock Liabilities.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 94.73% in 2020 and fell as far as 94.73% in 2020.
• Lyell Immunopharma's Preferred Stock Liabilities stood at $519.2 million in 2019, then surged by 94.73% to $1.0 billion in 2020, then changed by 0.0% to $1.0 billion in 2021.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $1.0 billion, $1.0 billion, and $1.0 billion for Q1 2021, Q4 2020, and Q3 2020 respectively.

Peer Comparison